Capricor

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Capricor and other ETFs, options, and stocks.

About CAPR

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. 

CEO
Linda Marbán
CEOLinda Marbán
Employees
231
Employees231
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1996
Founded1996
Employees
231
Employees231

CAPR Key Statistics

Market cap
465.69M
Market cap465.69M
Price-Earnings ratio
-3.27
Price-Earnings ratio-3.27
Dividend yield
—
Dividend yield—
Average volume
4.91M
Average volume4.91M
High today
$8.06
High today$8.06
Low today
$8.01
Low today$8.01
Open price
$7.90
Open price$7.90
Volume
13.68K
Volume13.68K
52 Week high
$40.37
52 Week high$40.37
52 Week low
$2.96
52 Week low$2.96

Stock Snapshot

The current Capricor(CAPR) stock price is $8.01, with a market capitalization of 465.69M. The stock trades at a price-to-earnings (P/E) ratio of -3.27.

On 2026-10-09, Capricor(CAPR) stock moved within a range of $8.01 to $8.06. With shares now at $8.01, the stock is trading 0.0% above its intraday low and -0.6% below the session's peak.

Trading activity shows a volume of 13.68K, compared to an average daily volume of 4.91M.

The stock's 52-week range extends from a low of $2.96 to a high of $40.37.

The stock's 52-week range extends from a low of $2.96 to a high of $40.37.

CAPR News

Investing.com 1d
Oppenheimer reiterates Capricor stock rating on FDA data robustness - Investing.com

...

Oppenheimer reiterates Capricor stock rating on FDA data robustness - Investing.com
TipRanks 4d
Capricor announces open-label extension data for Deramiocel

Capricor Therapeutics (CAPR) this morning announced new data from its ongoing HOPE-3 open-label extension study for its lead asset, Deramiocel, for the treatmen...

Analyst ratings

60%

of 10 ratings
Buy
40%
Hold
60%
Sell
0%

People also own

Based on the portfolios of people who own CAPR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.